Xiangxue Pharma Approved for China Trials of Brain Cancer Drug

Guangzhou Xiangxue Pharma received an IND approval from the CFDA to begin clinical trials of a novel treatment for glioblastoma. The candidate, KX-02, is a Src protein tyrosine kinase inhibitor that Xiangxue in-licensed from Athenex Pharma of New York State in 2012. KX-02 was granted the IND approval less than a year after filing (the wait time will be lowered to two months under new rules) as a Class 1 New Drug in China. Athenex received approval to begin US clinical trials for the drug in 2014. More details.... Share this with colleagues: // //